On September 3, 2019 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, reported it will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference at 10:50 a.m. Eastern time on Tuesday, September 10, 2019 (Press release, Trovagene, SEP 3, 2019, https://www.prnewswire.com/news-releases/trovagene-to-present-at-the-hc-wainwright-21st-annual-global-investment-conference-300909790.html [SID1234539215]). The conference is being held September 8-10, 2019 at the Lotte New York Palace Hotel.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Thomas Adams, Chief Executive Officer and Chairman, and Dr. Mark Erlander, Chief Scientific Officer of Trovagene, will provide an overview of the Company’s business during the live presentation and will be available for one-on-one meetings with investors.

Institutional investors who would like to attend the company’s presentation should click here to register for the conference. Once registered, you can log into the conference website to request a one-on-one meeting.

The presentation will be webcast live. To access the webcast, please click here. The webcast replay will remain available for 90 days following the live presentation.